PEG-MGF

Mechano growth factor is a natural muscle-repair signal, itself a variant of a protein called IGF-1 that muscle tissue produces after mechanical stress or injury; PEG-MGF is a chemically altered copy of that signal. A chemical tag called polyethylene glycol, or PEG, is fused onto it so it keeps working inside the body for a longer stretch before it breaks down. Researchers study how it wakes up dormant muscle stem cells, called satellite cells, mostly in cell cultures and animals rather than in people.

What it is

The natural form of this peptide, mechano growth factor, is a splice variant of IGF-1, meaning the body edits the same starting genetic message into a slightly different final protein. Muscle tissue makes it after mechanical stress, and it acts on satellite cells, a reserve population of stem cells that muscle fibers call on to repair themselves.

PEGylation, the chemical tag that gives PEG-MGF its name, is a common method researchers use to extend how long a peptide stays active in the body, and reports describe it stretching this peptide's activity from minutes to hours. Studies describe the peptide's E-peptide segment, the tail piece unique to this splice variant, as having its own distinct activity separate from mature IGF-1.

How it is studied

The research record for this peptide runs across mouse studies of muscle injury, human satellite cells grown in laboratory culture, and one human cell-transplantation study. It has not been tested for safety or effectiveness in a human clinical trial according to the sources reviewed for this entry.

What studies report

In mice with a chemically injured muscle, raising MGF levels above normal changed the pattern of inflammatory signals but actually slowed down, rather than sped up, the clearing of pro-inflammatory immune cells called macrophages from the injury site, and it did not clearly change how well the muscle regenerated. [1]
In a human cell study, the MGF E-peptide, the tail piece unique to this splice variant, significantly increased proliferation of muscle satellite cells taken from newborn and young adult donors, and extended how long those cells kept dividing before aging out, but this benefit did not appear in cells taken from one older adult donor. [2]
In a separate study using mice, injecting the same MGF E-peptide improved the success of transplanting human muscle precursor cells by changing how much the transplanted cells multiplied and matured, without harming their survival. [3]

What is not known

One study reviewed here found that raising MGF levels in injured mouse muscle slowed the clearing of inflammatory immune cells rather than speeding recovery, which cuts against a simple story of MGF as a pro-repair signal; the overall effect on muscle regeneration in that study was not clear either way. The clearest limitation in the human cell literature is the age-dependent result: the peptide helped young donor cells but not the one older donor's cells that were tested, and a single donor cannot establish how broadly this pattern holds across older people. No human clinical trial data exists for PEG-MGF itself, and how the pegylated version, rather than the natural unmodified peptide used in all of these studies, behaves in living tissue over time is not established.

Reported adverse findings

In the human cell study, the MGF E-peptide showed no proliferative benefit in muscle satellite cells from the older donor tested, unlike younger donor cells, an age-related difference in response rather than a reported toxicity. [2]
In the mouse injury study, raising MGF levels delayed the normal clearing of pro-inflammatory macrophages from the injury site, an effect the researchers linked to reduced programmed cell death in those immune cells rather than to any reported harm to the animals. [1]

Regulatory status

No regulatory body identified in the sources reviewed, including the FDA, has cleared PEG-MGF for use, and no published human clinical trial of it exists.